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Abstract. 
 
Invasive glioma cells migrate preferentially 
along central nervous system (CNS) white matter fiber 
tracts irrespective of the fact that CNS myelin contains 
proteins that inhibit cell migration and neurite out-
growth. Previous work has demonstrated that to mi-
grate on a myelin substrate and to overcome its inhibi-
tory effect, rat C6 and human glioblastoma cells require 
a membrane-bound metalloproteolytic activity (C6-
MP) which shares several biochemical and pharmaco-
logical characteristics with MT1-MMP. We show now 
that MT1-MMP is expressed on the surface of rat C6 
glioblastoma cells and is coenriched with C6-MP activ-
ity. Immunodepletion of C6-MP activity is achieved 
with an antiÐMT1-MMP antibody. These data suggest 
that MT1-MMP and the C6-MP are closely related or 
identical. When mouse 3T3 fibroblasts were transfected 
with MT1-MMP they acquired the ability to spread and 
migrate on the nonpermissive myelin substrate and to 
infiltrate into adult rat optic nerve explants. MT1-
MMPÐtransfected fibroblasts and C6 glioma cells were 
able to digest bNI-220, one of the most potent CNS my-
elin inhibitory proteins. Plasma membranes of both 
MT1-MMPÐtransfected fibroblasts and C6 glioma cells 
inactivated inhibitory myelin extracts, and this activity 
was sensitive to the same protease inhibitors. Interest-
ingly, pretreatment of CNS myelin with gelatinase
A/MMP-2 could not inactivate its inhibitory property. 
These data imply an important role of MT1-MMP in 
spreading and migration of glioma cells on white matter 
constituents in vitro and point to a function of MT1-
MMP in the invasive behavior of malignant gliomas in 
 
the CNS in vivo
 
.
 
Key words: MT1-MMP ¥ diffuse astrocytoma ¥ inva-
sion ¥ central nervous system ¥ metalloprotease
 
D
 
IFFUSE
 
 astrocytomas and especially glioblastoma
multiforme, the most common primary intracra-
nial tumor in humans, invade the brain preferen-
tially along white matter fiber tracts (Pedersen et al., 1995;
Giese et al., 1996; Kleihues and Cavenee, 1997). This rapid
infiltrative growth renders these tumors so dangerous and
prevents successful surgical resection. Interestingly, CNS
myelin is known as a very inhibitory substrate for neurite
outgrowth as well as for spreading and migration of sev-
eral cell types including astrocytes and fibroblasts (Schwab
and Caroni, 1988; Amberger et al., 1994; Spillmann et al.,
1997). A high molecular weight myelin protein (NI-220/
250/IN-1 antigen) plays a crucial role for this inhibitory
 
property of myelin (Caroni and Schwab, 1988; Paganetti
et al., 1988; Spillmann et al., 1998).
C6 rat glioma, a chemically induced highly invasive cell
line (Benda et al., 1968), as well as human glioma cells can
 
spread and migrate on a central nervous system (CNS)
 
1
 
myelin substrate in culture due to the presence of a mem-
brane-bound metalloprotease activity (C6-MP) by which
C6 cells overcome the inhibitory properties of CNS myelin
(Paganetti et al., 1988; Amberger et al., 1994, 1998; Hensel
et al., 1998). The nature of this protease activity has re-
mained undefined up to now.
The use of metalloproteases for tissue infiltration by tu-
mor cells is not uncommon. A number of studies have
shown that matrix metalloproteases (MMPs) play a major
role in physiological as well as pathological extracellular
 
matrix (ECM) remodeling (Rodgers et al., 1994; Stuve
et al., 1996; Yamamoto et al., 1996; Uhm et al., 1996,
1997). The MMP family is subdivided into four groups
based on the presence of specific protein domains: the
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minimal domain MMPs which contain the pre-, pro-, and
catalytic domains (matrilysin/MMP-7), the hemopexin do-
main MMPs which contain an additional terminal domain
sharing a structural similarity to hemopexin and vitronec-
tin (collagenases: MMP-1, 8, 13, 18; stromelysins: MMP-3,
10, 11 and metalloelastase MMP-12), the fibronectin do-
main MMPs (gelatinase A/MMP-2, gelatinase B/MMP-9),
and the transmembrane domain MMPs (MT-MMPs) (Na-
gase et al., 1997). MT1-MMP is an integral membrane
MMP and has been cloned from human placenta and
breast cancer cDNA libraries (Okada et al., 1995; Sato
et al., 1994). The physiological roles of MT1-MMP are not
fully understood: MT1-MMP can activate progelatinase
A/MMP-2 (Atkinson et al., 1995; Sato et al., 1996b; Butler et
al., 1998), but broad-spectrum proteolytic capacities have
also been demonstrated (Ohuchi et al., 1997; dÕOrtho et
al., 1998). MT1-MMP expression (along with gelatinase
A/MMP-2 and gelatinase B/MMP-9) correlates with the
malignancy of gliomas and also lung, cervical, and breast
cancer and melanomas (Rooprai and McCormick, 1997;
Okada et al., 1995; Yamamoto et al., 1996; Yoshizaki et al.,
1997; Tokuraka et al., 1995; Gilles et al., 1996; Polette et
al., 1996). Interestingly, the invasion of malignant mel-
anoma cells occurs only when MT1-MMP localizes on
plasma membrane invadopodia, which are cell membrane
protrusions contacting or invading the surrounding matrix
(Nakahara et al., 1997).
Here we show that C6 cells express active MT1-MMP
on their plasma membranes. The ability of C6 membranes
to inactivate the inhibitory substrate property of CNS my-
elin is lost after immunoprecipitation with an antiÐMT1-
MMP antibody whereas immunoprecipitation with an
antiÐMMP-2 antibody had no effect. MT1-MMPÐtrans-
fected mouse 3T3 fibroblasts behaved like C6 cells on
CNS white matter and infiltrate into optic nerve explants.
In addition to the spreading and migration ability on CNS
white matter as well as the degradation of the inhibitory
protein bNI-220 by MT1-MMPÐtransfected 3T3 fibroblasts
and C6 glioma cells, the MT1-MMPÐmediated activation
of gelatinase A/MMP-2 was sensitive to tissue inhibitor of
matrix metalloproteases (TIMP)2 and insensitive to TIMP1
and batimastat (BB94). Gelatinase A/MMP-2 did not mimic
the effect of MT1-MMP.
We conclude that MT1-MMP, but not gelatinase A/MMP-2
was able to remodel the nonpermissive CNS myelin sub-
strate into a permissive one thus allowing spreading, mi-
gration, and infiltration of glioma cells on a CNS myelin
substrate and, possibly, the invasion of myelinated CNS fi-
ber tracts in vivo.
 
Materials and Methods
 
Reagents and Materials
 
Rat C6 glioma cells were a kind gift of D. Monard (Friedrich Miescher In-
stitute, Basle, Switzerland) and mouse NIH 3T3 fibroblasts were obtained
from the American Type Culture Collection. Trypsin, iodacetamide,
PMSF, leupeptin, and pepstatin A were purchased from Fluka and
TIMP1, TIMP2, and the monoclonal antiÐMT1-MMP antibody (113-5B7)
were purchased from Fuji Chemical Industries. The tetrapeptide car-
bobenzoxy-Phe-Ala-Phe-Tyr-amide (cbz-FAFY-amide) was synthesized
by Bachem AG and BB94 was obtained from British Biotech Pharmaceu-
tical. Four-well cell culture dishes were bought from Greiner and teflon-
 
printed microscope slides were bought from Cell Line Associates. The cell
sedimentation manifold (Apex Manufacturing) used for the cell migration
assay was a kind gift of M. Berens (St. JosephÕs Hospital, Phoenix, AZ).
All products for zymography were bought from Bio-Rad. Nitrocellulose
membranes were from Micron Separations Inc. The enhanced chemilu-
minescence (ECL)-Western blot detection kit, antiÐMMP-2 antibody,
proMMP2, and active MMP-2 were from Chemicon. DME and Ca
 
2
 
1
 
/
Mg
 
2
 
1
 
-free HBSS, penicillin, and streptomycin were purchased from
GIBCO BRL and FCS was purchased from PAA. All other chemicals
were purchased from Sigma.
 
Cell Culture
 
Rat C6 glioma cells and mouse NIH 3T3 fibroblasts were cultured to 60Ð
80% confluency in DME, containing 10% heat-inactivated FCS (FCS/
DME). All culture media contained 100 U/ml penicillin and 100 
 
m
 
g/ml
streptomycin. Cells were harvested after a short trypsin treatment (0.1%
trypsin in 1 ml HBSS for 60 s) stopped by addition of 5 vol of FCS/DME,
and then followed by centrifugation (1,000 rpm, 6 min). Cells were resus-
pended in FCS/DME in presence of inhibitors of interest and used for the
experiments.
 
Preparation of Plasma Membrane-enriched
Cell Fractions
 
C6 cells were grown to confluency in roller bottles and collected as de-
scribed by Amberger et al. (1994). A 1-ml aliquot of this suspension was
stored immediately at 
 
2
 
20
 
8
 
C (cell homogenate fraction). Subcellular frac-
tionation was carried out as described by Hoffman et al. (1990) with some
minor modifications. In brief, the homogenate was centrifuged for 10 min
at 2,000
 
 g 
 
at 4
 
8
 
C, the pellet was collected and resuspended in 2 vol of 2.25 M
sucrose in PBS. The plasma membrane fraction was isolated by centrifu-
gation at 150,000 
 
g
 
 for 1 h at 4
 
8
 
C on a discontinuous sucrose density gradi-
ent at the 1.52Ð0.8 M sucrose interphase, resuspended in PBS, and then
stored in 500-
 
m
 
l fractions at 
 
2
 
70
 
8
 
C for further use. Plasma membranes
were pelleted, resuspended in 1 vol PBS containing 2 M NaCl, homoge-
nized, and then centrifuged for 1 h at 4
 
8
 
C at 100,000 
 
g
 
 to remove associ-
ated proteins. This salt-washed plasma membrane fraction (PM) was re-
suspended in PBS and 100-
 
m
 
l fractions were stored at 
 
2
 
70
 
8
 
C for further
use. The same procedure, on a smaller scale, was used for the preparation
of the fibroblast membranes.
 
Preparation of the bNI-220Ðenriched CNS Substrate
 
A CNS-derived inhibitory protein fraction was prepared as described by
Spillmann et al. (1997, 1998) with some modifications. In brief, bovine spi-
nal cord (obtained from Schlacthaus Der Stadt Zrich) was cleaned from
the meninges, minced, and subsequently homogenized on ice in 1 vol of
extraction buffer (100 mM Tris-HCl, pH 8.0, 60 mM CHAPS, 10 mM
EDTA, 2.5 mM iodacetamide, 1 mM PMSF, 0.1 
 
m
 
g/ml aprotonin, 1 
 
m
 
g/ml
leupeptin, and 1 
 
m
 
g/ml pepstatin A) and extracted for 10 min on a rotary
shaker. After pelleting the insoluble material at 100,000 
 
g
 
 for 1 h at 4
 
8
 
C,
the clear extract was enriched for inhibitory activity on a Q-Sepharose an-
ion exchange column. bNI-220 is a main inhibitory protein constituent of
this fraction.
 
Western Blotting
 
For the evaluation of bNI-220 degradation properties, 10 
 
m
 
g of the sam-
ples were incubated for 1 h at 37
 
8
 
C with 30 
 
m
 
g bNI-220Ðenriched CNS
substrate (see Cell Spreading Assay). Cell homogenates and plasma mem-
brane fractions were prepared as described above and analyzed by 10 or
5% (MT1-MMP blot, NI-220 blot, respectively) PAGE according to
Laemmli et al. (1970). The separated proteins were transferred onto a ni-
trocellulose membrane. The membrane was blocked with 3% gelatin in
TBS containing 1% Tween 20 (TBST) for 16 h at 4
 
8
 
C and probed with 5
 
m
 
g/ml antiÐMT1-MMP antibody or a rabbit anti-NI-220 polyclonal anti-
body 472 (1:5,000) (Huber et al., 1997). After extensive washing with
TBST, the membrane was incubated with goat antiÐmouse Ig coupled to
HRP or goat antiÐrabbit Ig coupled to HRP for 1 h at room temperature.
Finally, the blot was developed with the ECL-Western blot detection kit.
 
Zymography
 
Zymography was performed as described by Sawaya et al. (1996). In brief, 
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15 ng of proMMP2 were preincubated with 10 
 
m
 
g plasma membrane for 2 h
at 37
 
8
 
C and electrophoresed on 10% SDS-PAGE containing gelatin. Af-
ter electrophoresis, the gels were rinsed twice in 2.5% Triton X-100 and
incubated at 37
 
8
 
C for 20 h in 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM
CaCl
 
2
 
, and 0.02% Brij35. For the evaluation of the different protease in-
hibitors, the inhibitors were added to the development buffer; for the
evaluation of the effect of the inhibitors on the MT1-MMPÐmediated acti-
vation of proMMP-2, the plasma membranes were preincubated with the
inhibitors for 20 min at room temperature. The gels were stained with
0.5% Coomassie blue and destained in 40% methanol with 10% acetic
acid in H
 
2
 
O. Gelatinolytic activity was detected as transparent bands on
the blue background of the Coomassie-stained slab gel.
 
Immunocytochemistry
 
Cells were plated on CNS bNI-220Ðenriched substrate-coated wells (see
Cell Spreading Assay). After 1 h the cells were fixed for 15 min with pre-
warmed 4% paraformaldehyde in PBS at room temperature. After block-
ing the nonspecific binding sites with 3% gelatin in PBS, cells were incu-
bated over night at 4
 
8
 
C in 100 
 
m
 
l anti-human MT1-MMP antibody (5 
 
m
 
g/ml),
washed three times with PBS, and then reacted with TRITC-conjugated
goat antiÐmouse antibody (Jackson ImmunoResearch) for 1 h at room
temperature. Slides were embedded in Mowiol and evaluated under a
Zeiss Axiophot fluorescence microscope.
 
Immunodepletion
 
C6 plasma membranes were extracted with Triton X-100 (protein deter-
gent ratio 2:1) for 1 h at 4
 
8
 
C followed by centrifugation at 1 h at 100,000 
 
g
 
for 4
 
8
 
C). The supernatant was incubated for 1 h at room temperature with
0.05, 0.1, or 0.2 
 
m
 
g anti-human MT1-MMP monoclonal mouse antibody or
with 0.2, 1, or 2 
 
m
 
g of an antiÐMMP-2 polyclonal rabbit antibody. Anti-
mouse antibody- and anti-rabbit antibody-coated magnetic beads were
added and rotated for 30 min at room temperature. The beads were col-
lected and the supernatant was evaluated for its C6 metalloproteolytic ac-
tivity in the fibroblast spreading assay as described (Paganetti et al., 1988;
Amberger et al., 1994), with or without 
 
o
 
-phenanthroline to confirm me-
talloproteolytic activity.
 
Transfection of 3T3 Cells
 
The cDNA encoding human MT1-MMP (GenBank/EMBL/DDBJ acces-
sion number D26512) was isolated by nested polymerase chain reaction
(PCR). The first amplification was performed for 30 cycles at an annealing
temperature of 45
 
8
 
C using the oligonucleotide pair CCGTCGACAA-
AGGCGCCCCGAGGGA and AATCTAGAGGTAGGTGAGGCAG-
AGG with a human placenta cDNA library as template (Clontech). The
resulting 2.5-kb cDNA fragment was reamplified with the oligonucle-
otides CCGGTCGACTCGGACCATGTCTC and TTTCTAGAGCGT-
CAGACCTTGTCC for 40 cycles with annealing at 45
 
8
 
C, resulting in a
1.75-kb cDNA fragment containing the whole open reading frame of
MT1-MMP that was blunt endÐcloned in pUC19 (Invitrogen). The restric-
tion sites XbaI and SalI present in the oligonucleotides (underlined se-
quences) were used for subcloning in the pRK vector (Ruat et al., 1995).
C6 cells and 3T3 cells were cultured as described. On the day of trans-
fection, fibroblasts were washed with HBSS. A DNA mix was prepared by
adding 10 
 
m
 
g MT1-MMPÐplasmid to 300 
 
m
 
l HBSS and 60 
 
m
 
l SuperFect, as
described by the manufacturer (Qiagen). After 10 min of incubation at
room temperature, 3 ml FCS/DME were added. HBSS was removed from
the culture dishes and the DNA mix was added. The dishes were incu-
bated at 37
 
8
 
C for 3 h, another 3 ml of FCS/DME were added, and cells
were evaluated after 48 h.
 
Cell Spreading Assay
 
The Q pool protein concentration resulting in 80% inhibited 3T3 fibro-
blasts was determined and used for all further experiments. After 1 h of
incubation, inhibited fibroblasts remained round in contrast to well-
attached, flat, spreading cells on a control substrate. The Q pool fraction
was coated overnight at 4
 
8
 
C onto four-well culture dishes; control dishes
were coated with extraction buffer only. Unbound material was removed
by two washes with HBSS and 8,000 fibroblasts in FCS/DME were plated
per well (1 cm
 
2
 
). After 1 h of incubation at 37
 
8
 
C the cells were fixed with
4% paraformaldehyde in PBS. The portion of flat, well-spread cells was
determined (200Ð300 cells counted per well). Protease inhibitors were
added directly to the cell suspension 15 min before plating from 100
 
3
 
solutions (final concentrations: 1 mM EDTA, 200 
 
m
 
M 
 
o
 
-phenanthroline,
300 
 
m
 
M phosphoramidon, 10 
 
m
 
M Cbz-Phe-Ala-Phe-Tyr-amide, 1 
 
m
 
M
BB94, 100 nM TIMP1, and 100 nM TIMP2).
To investigate the influence of active gelatinase A/MMP-2 and of C6
cell homogenate (CH) and plasma membranes of C6 cells, MT1-MMPÐ
and mock-transfected fibroblasts on the CNS myelin inhibitory properties,
the coated Q pool was treated for 1 h at 37
 
8
 
C with 10 
 
m
 
M active gelatinase
A/MMP-2, 50 
 
m
 
g CH, or 30 
 
m
 
g PM and washed two times with HBSS be-
fore plating fibroblasts. Every experiment was performed at least three
times in triplicate.
 
Cell Migration Assay
 
The migration assay was performed as described by Berens et al. (1994)
and Amberger et al. (1998), with some modifications. In brief, teflon-
printed microscope slides, subdivided into 10 wells, were precoated over-
night with 50 
 
m
 
g/ml poly-
 
L
 
-lysine, washed twice with PBS, air dried, and
then stored at room temperature until use. Subsequently, six wells were
coated overnight with the CNS inhibitory protein fraction at 4
 
8
 
C, four
controls were coated with extraction buffer only. After two washes with
HBSS, the wells were covered with 70 
 
m
 
l FCS/DME each (with or without
inhibitors), the cell sedimentation manifold was placed on the slide, and
1 
 
m
 
l of cell suspension (2,000 cells) was placed in each cylinder. Protease
inhibitors were added directly to the cell suspension 15 min before plating
from 100
 
3
 
 solutions. After incubation for 2 h at 37
 
8
 
C under 5% CO
 
2
 
, the
cell sedimentation manifold was removed. The area covered with cells was
recorded 2, 6, 12, and 24 h after seeding with a video camera (charge-cou-
pled device [CCD]; Sony) attached to an inverted microscope (2.5
 
3
 
 ob-
jective, IMT-2; Olympus). The cell migration area was quantified with an
image analysis system (Image-1; Universal Imaging). The migration area
2 h after seeding was used as the migration reference point; all values
measured were divided by the 2-h value to obtain a relative migration
area. Every experiment was performed at least three times in triplicate for
the CNS substrate and in duplicate for the control substrate.
 
Optic Nerve Explant Infiltration Assay
 
Optic nerve explants in chamber cultures were prepared as described by
Schwab and Thoenen (1985). In brief, the optic nerves were rapidly dis-
sected from 3Ð4-mo-old Lewis rats and then trimmed. Subsequently, the
nerves were X-irradiated at 5,000 
 
g
 
 for 7 min to reduce glial cell prolifera-
tion and placed under a teflon ring sealed to a culture dish with silicon
grease. Three chambers in contact only via the explants were obtained in
this way (see Fig. 9 a). C6 glioblastoma cells, MT1-MMPÐtransfected, or
mock-transfected fibroblasts were prelabeled with Hoechst-dye for 1.5Ð3 h
(50 
 
m
 
l Hoechst-dye/10 ml DME/FCS), washed three times with DME/
FCS, and then 100,000 cells were placed into the middle chamber. Cul-
tures were incubated for 7 d. Medium was exchanged every other day. At
the end of the experiment the optic nerves were fixed for 48 h in 4% PFA
containing 5% sucrose, washed, removed from the cultures, flat mounted
in Tissue Tek (Sakura), and then frozen at 
 
2
 
40
 
8
 
C. 20-
 
m
 
m longitudinal sec-
tions were serially cut on a cryostate. Labeled infiltrated cells were
counted under a fluorescences microscope (Zeiss Axiophot) starting from
the tip of the nerve exposed to the middle, cell-containing chamber. The
cells were counted at distances of 0.4Ð0.8, 0.8Ð1.2, and 1.2Ð1.8 mm from
the middle chamber stump. Three sections were counted for each dis-
tance, and the cell numbers were extrapolated for the thickness of the
nerve. 12 nerves infiltrated by MT1-MMPÐtransfected fibroblasts, 12
nerves with mock-transfected fibroblasts, and eight nerves with C6 cells
were evaluated.
 
Results
 
Active MT1-MMP Is Localized on the Plasma 
Membrane of C6 Glioblastoma Cells and Is Coenriched 
with the C6 MP Activity
 
To determine if MT1-MMP is expressed on the surface of
C6 glioblastoma cells, cells were plated on a CNS inhibi-
tory protein substrate for 1 h. The cells were firmly at-
tached and well spread assuming the typical fried egg
appearance. Immunofluorescence with a monoclonal antiÐ 
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MT1-MMP antibody revealed staining along the plasma
membrane (Fig. 1 a) often enriched at substrate contact
sites (Fig. 1 b).
To biochemically evaluate the localization of MT1-
MMP, a C6 total cell homogenate and a salt-washed C6
plasma membrane fraction were prepared. These fractions
were separated on 10% SDS-PAGE and blotted. Incuba-
tion of the blots with antiÐMT1-MMP antibody revealed
two specific bands: one at the molecular weight of pro-
MT1-MMP (63 kD) and another band at 58 kD, corre-
sponding to the molecular weight of active MT1-MMP
(Fig. 2 a) (Ohuchi et al., 1997). The 58-kD band was
clearly more intense in the plasma membrane fraction
than in the cell homogenate fraction.
C6-MP activity, as determined in a cell spreading assay,
was also highest in the C6 plasma membrane fraction and
lower in the C6 cell homogenate (Fig. 2 b) (Paganetti et al.,
1988, Amberger et al., 1994). The presence of active MT1-
MMP was confirmed by zymography where plasma mem-
branes of C6 cells as well as of MT1-MMPÐtransfected fi-
broblasts showed conversion of progelatinase A/proMMP-2
to mature MMP-2 (Fig. 3, lanes 1Ð7). These results show
the presence of active MT1-MMP on the plasma mem-
branes of C6 glioblastoma cells.
 
Depletion of C6 Glioblastoma Plasma Membrane 
Extract with MT1-MMP Antibody Leads to Loss of 
Remodeling Ability of the Inhibitory CNS
Myelin Substrate
 
C6 plasma membrane detergent extracts, containing C6
metalloproteolytic activity (Amberger et al., 1994), were
treated with a MT1-MMP antibody or a MMP-2 antibody.
After immunoprecipitation with MT1-MMP antibody, the
extracts showed a large decrease of their ability to inacti-
vate the inhibitory effect of CNS membrane proteins for
Figure 1. MT1-MMP immunoreactivity in C6 glioblastoma cells
and MT1-MMPÐtransfected fibroblasts 1 h after plating the cells
on CNS substrate. (a) Well-spread C6 cell shows diffuse MT1-
MMP staining over the plasma membrane, especially along the
cell periphery. (b) When the plane of focus is at the level of the
substrate, MT1-MMP immunoreactivity is detected at the sub-
strate contact sites. (c) MT1-MMPÐtransfected fibroblasts show
immunoreactivity enriched on lamellipodia (arrows). (d) 24 h af-
ter plating MT1-MMPÐtransfected fibroblasts cells formed long
processes on which foci of MT1-MMP are observed (arrowhead).
Bar, 14 mm.
Figure 2. MT1-MMP Western blot and remodeling of the CNS
inhibitory substrate. (a) Western blots of cell lysates and salt-
washed plasma membranes using a monoclonal antibody against
MT1-MMP. The protein fractions were electrophoresed on a
10% SDS polyacrylamide gel, blotted onto a nitrocellulose mem-
brane, and probed with MT1-MMP antibody. Bound antibody
was visualized by peroxidase-conjugated second antibody and
chemiluminescence. Lane 1, C6 cell homogenate (CH C6); lane
2, C6 cell plasma membranes (PM C6); lane 3, plasma mem-
branes of MT1-MMPÐtransfected fibroblasts (PM MT); lane 4,
plasma membranes of mock-transfected fibroblasts (PM Mo).
Molecular mass markers are indicated at the left side, proMT1-
MMP and processed MT1-MMP (arrows) on the right. Two non-
specific bands are seen between the pro- and mature MT1-MMP
forms since they are visualized also in the absence of primary an-
tibody. (b) Culture dishes coated with inhibitory CNS membrane
proteins were pretreated in different ways and their inhibitory
activity assayed for 3T3 fibroblast spreading. Treatment with C6
homogenate (50 mg) or plasma membranes (30 mg) of C6 glioma
cells or MT1-MMPÐtransfected fibroblasts reduced the inhibitory
property significantly, whereas plasma membranes of mock-
transfected fibroblasts did not. Pretreatment of the CNS sub-
strate with gelatinase A/MMP-2 (0.1, 1, and 10 mM) did not influ-
ence its nonpermissive substrate property. Values are means 6
SEM of three experiments performed in triplicate. Significance
with the two-tailed StudentÕs t test: P , 0.01 (**). 
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fibroblast spreading (Fig. 4). This effect was dose depen-
dent. Immunoprecipitation with a MMP-2 antibody had
no effect (Fig. 4).
 
Active MT1-MMP Is Present on the Plasma Membrane 
of MT1-MMPÐtransfected Fibroblasts
 
1 h after plating on a bNI-220Ðenriched CNS substrate,
MT1-MMP immunoreactivity was mainly localized on the
lamellipodia of the transfected fibroblasts (Fig. 1 c). This
lamellipodial staining was absent in mock-transfected cells
(data not shown). About 15% of the cells showed this typ-
ical surface staining. 24 h after plating of the cells on CNS
myelin, the MT1-MMPÐtransfected fibroblasts showed
long processes on which foci of high MT1-MMP expres-
sion were found (Fig. 1 d).
Western blots demonstrated that the plasma mem-
branes of MT1-MMPÐtransfected fibroblasts as well as
 
those of mock-transfected fibroblasts contained proMT1-
MMP, but only the MT1-MMPÐtransfected fibroblasts ex-
pressed the mature form (Fig. 2 a). Pretreatment of the in-
hibitory CNS protein substrate with plasma membranes of
MT1-MMPÐtransfected fibroblasts revealed a large de-
crease in the inhibitory substrate property as observed by
an increase in the spreading of fibroblasts on the pre-
treated substrate (Fig. 2 b). Pretreatment of the substrate
with membranes of mock-transfected fibroblasts had no
effect (Fig. 2 b).
Zymography showed that only the plasma membranes
of MT1-MMPÐtransfected fibroblasts were able to medi-
ate progelatinase A/proMMP-2 conversion to mature ge-
latinase A/MMP-2 and a band shift from the 72-kD pro-
gelatinase A/proMMP-2 to 59-kD gelatinase A/MMP-2.
Again plasma membranes of mock-transfected fibroblasts
were inactive in this assay (Fig. 3).
 
MT1-MMPÐtransfected Fibroblasts Spread on an 
Inhibitory CNS Protein Substrate and Are Sensitive to 
the Same Protease Inhibitors as C6 Glioblastoma Cells
 
To evaluate the ability of MT1-MMPÐtransfected, mock-
transfected, and nontransfected fibroblasts to spread on an
inhibitory CNS membrane protein extract (Spillmann et al.,
1998), the cells were plated on this substrate, fixed after 1 h
of incubation, and then the percentage of flat, well-
attached, spread cells was determined (Fig. 5). Of the non-
Figure 3. Gelatin zymography. ProMMP-2 (lane 1) is partially
converted to mature MMP-2 by C6 plasma membranes (PM C6)
(lane 2), or MT1-MMPÐtransfected fibroblast plasma mem-
branes (PM MT) (lane 4), but not by mock-transfected fibroblast
plasma membranes (PM Mo) (lane 6). Plasma membranes alone
(PM C6, lane 3; PM MT, lane 5; PM Mo, lane 7) neither contain
mature nor proMMP-2. Conditioned media of C6 cells (lane 8),
MT1-MMPÐtransfected fibroblasts (lane 9) and mock-trans-
fected fibroblasts (lane 10) contain active and proMMP-2. Effects
of protease inhibitors: MMP-2 is strongly inhibited by 100 nM
TIMP2 (lane 12 versus lane 11) and 1 mM BB94 (lane 14), but not
by 100 nM TIMP1 (lane 13). Conversion of proMMP-2 to mature
MMP-2 by MT1-MMPÐtransfected fibroblast plasma membranes
is decreased by TIMP2 (100 nM, lane 16 versus lane 15), but not
by TIMP1 (100 nM, lane 17) or BB94 (1 mM).
Figure 4. C6 plasma membrane extracts depleted of MT1-MMP
by immunoprecipitation can no more inactivate the inhibitory ac-
tivity of CNS myelin for fibroblast spreading, whereas immu-
nodepletion of gelatinase A/MMP-2 did not affect the inactiva-
tion potential of the extract. 40 mg of C6 plasma membrane
detergent extracts were immunodepleted with the indicated
amounts antiÐMT1-MMP antibody or antiÐMMP-2 antibody. In-
hibitory CNS substrate-coated wells were subsequently incu-
bated for 30 min at 378C with the immunodepleted extracts (su-
pernatants), washed, and then used to evaluate the spreading
ability of normal fibroblasts. Values are means 6 SEM of two ex-
periments performed in triplicate. Significance with the two-
tailed StudentÕs t test: P , 0.1 (*); P , 0.01 (**). 
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transfected and mock-transfected fibroblasts 19 
 
6
 
 2 and
20 
 
6
 
 2%, respectively, of the cells were able to spread on
the CNS protein substrate. Upon transfection with MT1-
MMP the percentage of spread cells increased to 35 
 
6
 
 3%
(Fig. 5 b). This increase of 15% correlates well with the
transfection rate of about 15% as seen in immunofluores-
cence for MT1-MMP. On the control substrate (PLYS),
MT1-MMPÐ, mock-, and nontransfected fibroblasts spread
equally well.
The effects of several metalloprotease inhibitors on the
spreadings of MT1-MMPÐtransfected fibroblasts (Fig. 6 a)
and of C6 glioblastoma cells (Fig. 6 b) plated on an inhibi-
tory CNS protein substrate were studied. In contrast to
normal 3T3 fibroblasts (Fig. 2 b, Fig. 4, and Fig. 5 b), MT1-
MMPÐtransfected fibroblasts as well as C6 cells show a
large proportion of spreading cells. Addition of the chela-
tors EDTA and 
 
o
 
-phenanthroline greatly reduced the
spreading ability of both cell types (
 
P
 
 , 
 
0.01). The more
specific C6-MP inhibitors phosphoramidon and cbz-
FAFY-amide (Amberger et al., 1994) also significantly
reduced the spreading ability of MT1-MMPÐtransfected
fibroblasts similar to what was observed with the C6 glio-
blastoma cells.
 
In vivo, the activity of MMPs is regulated by tissue me-
talloproteinase inhibitors (TIMP1 to TIMP4). TIMP2 ex-
erts activity against several MMPs, but preferentially
against gelatinase A/MMP-2 by binding both its latent and
active forms (Imai et al., 1996). The TIMP2 effect on MT1-
MMP has been extensively studied and optimal inhibitory
concentrations for TIMP2 have been assessed (Atkinson
et al., 1995; Sato et al., 1996b; Butler et al., 1998). TIMP1 is
active against several MMPs, but preferentially against ge-
latinase B/MMP-9 (Birkedal-Hansen et al., 1993). BB94,
which is a synthetic general inhibitor of MMPs, has been
used in clinical trials for treatment of several tumors based
on its inhibitory effect on gelatinase A/MMP-2 (Wojtow-
icz-Praga et al., 1997). 1 
 
m
 
M BB94 and 100 nM TIMP1
had no effect on spreading of C6 cells as well as MT1-
MMPÐtransfected fibroblasts (Fig. 6). Interestingly, 100 nM
Figure 5. (a) Spreading of MT1-MMPÐtransfected fibroblasts on
culture dishes coated with inhibitory CNS membrane protein ex-
tracts. 1 h after plating z35% of the MT1-MMPÐtransfected cells
were well attached and showed a flat appearance (arrow). The
nonspreading cells appear as round, phase-bright cells. (b) Quan-
tification of the spreading of MT1-MMPÐ, mock-, and non-
transfected fibroblast on CNS inhibitory substrate and control
substrate (PLYS). Significantly more MT1-MMPÐtransfected fi-
broblasts spread on CNS myelin as compared with mock- or non-
transfected fibroblasts. In all three conditions, cells spread
equally well on the control substrate PLYS. Values are means 6
SEM of three experiments, performed in triplicate. Significance
with the two-tailed StudentÕs t test: P , 0.01 (**).
Figure 6. Effect of various metalloprotease inhibitors on the
spreading ability of MT1-MMPÐtransfected fibroblasts and C6
glioma cells on CNS myelin. (a) Transiently MT1-MMPÐtrans-
fected fibroblasts of which only z15% express high MT1-MMP
levels. The proportion of spreading cells on CNS myelin substrate
was reduced by 15% by 1 mM EDTA, 200 mM o-phenanthroline
(phen), 300 mM phosphoramidon (phos), 10 mM Cbz-Phe-Ala-
Phe-Tyr-amide (FAFY), and 100 nM TIMP2. No inhibition was
observed in presence of 1 mM BB94 or 100 nM TIMP1. (b)
About 80% of the C6 cells spread on the inhibitory CNS myelin
substrate. This was reduced to z25% by the same inhibitors
found to affect the MT1-MMPÐtransfected fibroblasts. Values
are means 6 SEM of three experiments, performed in triplicate.
Significance with the two-tailed StudentÕs t test: P , 0.01 (**).Belin et al. Role of MT1-MMP in Diffuse Astrocytomas 379
TIMP2 strongly reduced the spreading capacity of the
MT1-MMPÐtransfected 3T3 fibroblasts as well as that of
the C6 glioblastoma (Fig. 6). Spreading on control sub-
strate was not influenced by these inhibitors (data not
shown). The activity profile of the inhibitors at the concen-
trations used in the bioassays was confirmed by zymogra-
phy: gelatin degradation by MMP-2 was strongly reduced
by 100 nM TIMP2 and 1 mM BB94. In contrast, 100 nM
TIMP1 had only a small effect (Fig. 3). These data strongly
suggest an involvement of MT1-MMP in the mechanism
that allows C6 cells to overcome the inhibitory property of
CNS membranes, and that gelatinase A/MMP-2 and gelati-
nase B/MMP-9 do not play a major role in spreading of
these cells on CNS myelin.
Gelatinase A/MMP-2 Does Not Account for the 
Inactivation of the bNI-220Ðenriched Inhibitory CNS 
Protein Substrate
Pretreatment of an inhibitory bovine spinal cord protein
fraction (Spillmann et al., 1998) with active gelatinase
A/MMP-2 (activity status confirmed by zymography: Fig.
3, lanes 11Ð14) did not transform this nonpermissive CNS
protein substrate into a permissive one, since no increase
in the spreading ability of fibroblasts on this substrate was
observed (Fig. 2 b). On the other hand, the MMP inhibitor
BB94 had neither effect on the spreading of C6 glioma
cells, nor on that of MT1-MMPÐtransfected fibroblasts
(Fig. 6). Mock-transfected fibroblasts were not able to
spread on this inhibitory CNS protein substrate although
they do express active gelatinase A/MMP-2 as shown by
zymography (Fig. 3, lane 10). In addition, by zymography
we did not detect active gelatinase A/MMP-2 in the plasma
membrane fractions of C6 or MT1-MMPÐtransfected cells
(Fig. 3, lanes 3 and 5). Thus, the ability of cells to spread
on a CNS myelin protein substrate correlates well with the
presence of active MT1-MMP, but not with that of active
gelatinase A/MMP-2.
MT1-MMPÐtransfected Fibroblasts Migrate on an 
Inhibitory CNS Myelin Substrate and Are Sensitive to 
the Same Inhibitors as the C6 Glioblastoma Cells
To determine the involvement of MT1-MMP in cell migra-
tion on CNS myelin, cells were seeded on the inhibitory
CNS protein substrate or on PLYS control substrate with
the help of the cell manifold holder in a round, well-
defined area. 24 h after seeding, MT1-MMPÐtransfected
3T3 cells showed a large increase in the migration area
compared with 2 h after seeding (Fig. 7 a and Fig. 8). In
contrast, mock-transfected fibroblasts had hardly migrated
out of the starting area (Fig. 8). At the rim of the migra-
tion zone single MT1-MMPÐtransfected cells were moving
on the CNS myelin substrate (Fig. 7, b and c). This strongly
indicates that these cells were not pushed out of the center
due to proliferation effects. Since the transfection rate was
z15%, only a minor population of MT1-MMPÐtrans-
fected fibroblasts would be expected to migrate out of the
starting area. However, more than 15% migrating cells
were observed. Typically, the cells at the front of the mi-
gration zone often were characterized by long processes
(Fig. 7 c). Immunofluorescence for MT1-MMP revealed
that these cells were strongly MT1-MMP positive (Fig. 7 d).
Cells in the center of the migration area often had shorter
processes on which less MT1-MMP was expressed. The
ÒpioneersÓ may have proteolytically modified the inhibi-
tory CNS substrate, allowing also non- or low MT1-MMPÐ
expressing cells to migrate. The time-course of fibroblast
migration is shown in Fig. 8. MT1-MMPÐtransfected fibro-
blasts almost doubled the area covered with cells within 24 h,
whereas mock-transfected cells could hardly migrate on
Figure 7. MT1-MMPÐtrans-
fected fibroblasts migrate on
CNS myelin. (a) MT1-MMPÐ
transfected fibroblasts were
plated in a defined area
(marked by circle). After 24 h
the area covered with cells
doubled in size. (b and c) En-
largements of the rim of the
migration zone show the mi-
gration of single MT1-MMPÐ
transfected cells. (d) These
ÒpioneerÓ cells are expressing
high levels of MT1-MMP
with foci of MT1-MMP on
their processes as shown by
MT1-MMP immunostaining
(same field as c). Bars: (a)
300  mm; (b) 150 mm; (c and d)
50 mm.The Journal of Cell Biology, Volume 144, 1999 380
the inhibitory substrate. Both cell types were migrating
equally well on the control substrate.
The influence of the metalloprotease inhibitors BB94
(1 mM), TIMP1 (100 nM), and TIMP2 (100 nM) on the mi-
gration of MT1-MMPÐtransfected fibroblasts (Table I,
top) and C6 glioblastoma cells (Table I, bottom) was eval-
uated. BB94 and TIMP1 did not show a significant effect.
In contrast, TIMP2 decreased the migration capacity of
both C6 glioblastoma cells and MT1-MMPÐtransfected fi-
broblasts massively (P , 0.01). For either cell type, migra-
tion on the control substrate was not influenced by these
inhibitors (data not shown).
MT1-MMPÐtransfected Fibroblasts Infiltrate into Optic 
Nerve Explants
Pairs of adult rat optic nerves were cultured in a three-
compartment chamber culture and Hoechst dye-labeled
cells were placed at one end of the nerve explants (Fig.
9 a). After 7 d in vitro the distance of cell infiltration
was evaluated on longitudinal histological sections. Mock-
transfected fibroblasts did not infiltrate the CNS explants
for more than 0.8 mm. In contrast, large numbers of the
MT1-MMPÐtransfected fibroblasts infiltrated over 1Ð1.6
mm into the optic nerve, distances very similar to those
seen with C6 glioblastoma cells (Fig 9, bÐd). Quantifica-
tion and distance of fibroblast infiltration is shown in Fig.
10. MT1-MMP expression thus enables fibroblasts to infil-
trate this adult CNS tissue rich in myelin.
Plasma Membranes of MT1-MMPÐtransfected 
Fibroblasts Can Degrade the Potent CNS Myelin 
Inhibitory Protein bNI-220
A bovine spinal cord detergent extract enriched for bNI-
220 over an ion-exchange column was preincubated with
plasma membranes of mock- and MT1-MMPÐtransfected
fibroblasts. Western blots with an affinity-purified rabbit
polyclonal antibody against a bNI-220 peptide sequence
(Ab 472; Huber et al., 1998) revealed disappearance or
diminution of the bNI-220 band after treatment with
plasma membranes of MT1-MMPÐtransfected fibroblasts
or of C6 glioma cells, but not after treatment with mem-
branes of mock-transfected fibroblasts (Fig. 11). This deg-
radation could be inhibited by the addition of 100 nM
TIMP2, but not by the addition of 1 mM BB94 or 100 nM
TIMP1 (Fig. 11). We conclude that NI-220 can be de-
graded specifically by MT1-MMPÐenriched plasma mem-
branes.
Discussion
Neoplastic cells of peripheral origin which produce me-
tastases in the brain rarely infiltrate the parenchyma of the
CNS. Instead, they grow as solid, well-circumscribed tu-
mors (Laerum et al., 1984; Bindal et al., 1994). Diffuse
astrocytomas, including glioblastoma multiforme, on the
other hand massively invade the brain by migrating prefer-
entially along the white matter fiber tracts (Pedersen et al.,
1995; Kleihues and Cavenee, 1997). In vitro, the motility
of most cells, e.g., astrocytes or fibroblasts, is strongly re-
stricted on a CNS white matter substrate due to the pres-
ence of inhibitory constituents, in particular the potent in-
hibitory protein NI-220/250 (Spillmann et al., 1997, 1998;
Caroni and Schwab, 1988). Rat C6 glioma cells were
shown to spread and migrate on CNS myelin and infiltrate
CNS tissue in vitro and in vivo (Paganetti et al., 1988;
Goldberg et al., 1991). C6 cells as well as human glioma
cell lines use a membrane-bound MP activity (C6-MP) to
overcome the inhibitory properties of CNS myelin (Paga-
netti et al., 1988; Amberger et al., 1994, 1998; Hensel et al.,
1998). This C6-MP activity correlates with the malignancy
of gliomas (Amberger et al., 1998), a characteristic shared
by an other membrane bound metalloprotease: the MT1-
MMP (Okada et al., 1995; Yamamoto et al., 1996; Yo-
shizaki et al., 1997). We therefore suspected a similarity
Figure 8. Time-course and quantification of 3T3 fibroblast mi-
gration. MT1-MMPÐtransfected fibroblasts migrated extensively
on inhibitory CNS protein substrate within 24 h, in contrast to
mock-transfected fibroblasts, whereas both migrated equally well
on the control substrate (PLYS). Values are means 6 SEM of
four experiments, performed in quadruplicate. Significance with
the two-tailed StudentÕs t test: P , 0.01 (**).
Table I. Effect of Metalloprotease Inhibitors on Cell Migration
Inhibitor
Relative
migration area
Percent
reduction in
migration ability
MT1-MMPÐtransfected
fibroblasts on myelin None 1.88 6 0.04 0 6 4.5
BB94 1.78 6 0.03 11.4 6 3.4
TIMP1 1.82 6 0.06 6.8 6 6.8
TIMP2 1.28 6 0.07 68.2 6 8.0
C6 glioblastoma cells on myelin None 2.02 6 0.06 0 6 5.9
BB94 1.94 6 0.05 7.8 6 4.9
TIMP1 2.03 6 0.06 0 6 5.9
TIMP2 1.21 6 0.07 78.4 6 6.9
Effect of specific metalloprotease inhibitors on the migration capacity of MT1-
MMPÐtransfected fibroblasts and C6 glioblastoma cells on an inhibitory CNS protein
substrate (24 h). Top, the migration of MT1-MMPÐtransfected fibroblasts was not af-
fected by 1 mM BB94 or 100 nM TIMP1, but was greatly decreased by 100 nM
TIMP2. Bottom, C6 cells showed an inhibitor profile very similar to that of the MT1-
MMPÐtransfected fibroblasts. Values are means 6 SEM of three experiments per-
formed in quadruplicate. Significance with the two-tailed StudentÕs t test: P , 0.01
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(or even identity) of the C6-MP activity with MT1-MMP.
This hypothesis is supported by the present results: (a) im-
munohistochemistry, Western blots, and zymography re-
vealed the expression of active MT1-MMP by C6 cells;
(b) C6-MP activity was immunodepleted from C6 plasma
membrane extracts with an antibody against MT1-MMP
but not by an antibody against gelatinase A/MMP-2; and
(c) 3T3 fibroblasts, which can not spread or migrate on a
CNS inhibitory protein substrate, were able to do so upon
transfection with MT1-MMP. Furthermore, (d) spreading
Figure 9. (a) Optic nerve explant infiltra-
tion assay. Adult rat optic nerves were
placed underneath a teflon ring sealed to a
culture dish with silicon grease. Hoechst
dye-prelabeled C6 cells, MT1-MMPÐtrans-
fected fibroblasts, or mock-transfected fi-
broblasts (100,000 cells) were placed in the
middle chamber, in contact with the tips of
the nerves (a). After 7 d Hoechst dye-labeled
cells are observed infiltrating the optic
nerve explants in longitudinal sections.
MT1-MMPÐtransfected fibroblasts (b) but
not mock-transfected fibroblasts (c) infil-
trated the optic nerves. Enlargements show
a high density of MT1-MMPÐtransfected fi-
broblasts at a distance of 1.6 mm. Very few
mock-transfected fibroblasts were found at
this depth. C6 cells infiltrated the optic
nerve to the same extent as the MT1-MMPÐ
transfected fibroblasts (d). Bar, 0.3 mm.The Journal of Cell Biology, Volume 144, 1999 382
and migration of MT1-MMPÐtransfected fibroblasts and
of C6 glioblastoma cells on a CNS myelin substrate were
affected in the very same way by several inhibitors of metal-
loprotease: both cell types were sensitive to the chelators
EDTA and o-phenanthroline, to phosphoramidon and the
tetrapeptide cbz-FAFY-amide, inhibitors which were shown
earlier to affect the C6-MP activity (Amberger et al.,
1994). Both cell types were also affected by 100 nM
TIMP2. At this concentration TIMP2 acts as an inhibitor
for MT1-MMP and gelatinase A/MMP-2 (Atkinson et al.,
1995; Sato et al., 1996b; Butler et al., 1998). Neither C6
cells nor MT1-MMPÐtransfected cells were affected by
100 nM TIMP1 or by 1 mM BB94. Both strongly inhibit ge-
latinase A/MMP-2 and gelatinase B/MMP-9, respectively,
at this concentration.
Plasma membranes of MT1-MMPÐtransfected fibro-
blasts were able to mediate progelatinase A/MMP-2 acti-
vation, an ability which was blocked by the addition of 100
nM TIMP2, whereas 100 nM TIMP1 had no effect. Inter-
estingly, 1 mM BB94 had no effect on MT1-MMPÐmedi-
ated proMMP-2 activation. The effects of TIMP1 and
TIMP2 confirm an earlier report: dÕOrtho et al. (1998)
showed that expression of MT1-MMP on the cell surface
caused proteolysis of a gelatin film, which is inhibited by
TIMP2 but not by TIMP1.
Although MT1-MMP can act as an activator of pro-
MMP-2, it has been hypothesized that the ability of MT1-
MMPÐtransfected cells for an elevated invasive potential
may not necessarily be linked exclusively to progelatinase
A/MMP-2 activation; MT1-MMP possesses direct degrad-
ing activity for number of ECM components and receptors
(Ohuchi et al., 1997; dÕOrtho et al., 1997; Pei and Weiss,
1996). The present results show the inability of soluble ge-
latinase A/MMP-2 to remodel the nonpermissive CNS
protein substrate into a permissive one. Gelatinase A/MMP-2
immunodepleted C6 plasma membrane detergent extract,
containing C6 metalloproteolytic activity, was still able to
inactivate the inhibitory effect of the CNS white matter
substrate, whereas MT1-MMP depleted extract could not.
Potent gelatinase A/MMP-2 and gelatinase B/MMP-9 in-
hibitors (BB94 and TIMP1) did not affect C6 glioma cells
or MT1-MMPÐtransfected fibroblasts in their spreading
and migration ability on CNS myelin, thus supporting the
view that MT1-MMP may directly remodel the CNS sub-
strate and allow C6 cell motility without the involvement
of soluble MMPs.
Plasma membranes of C6 cells and of MT1-MMPÐtrans-
fected fibroblasts were able to convert the nonpermissive
substrate into a permissive one for cell spreading, whereas
mock-transfected fibroblast plasma membranes failed to
do so. Furthermore, degradation of the inhibitory protein
bNI-220 occurred by C6 plasma membranes and by the
MT1-MMPÐtransfected fibroblasts, but not by plasma mem-
branes of mock-transfected fibroblasts. These results show
that MT1-MMP is crucial for the inactivation of inhibitory
constituents of the CNS, a process which allows the migra-
tion of glioma cells and of MT1-MMPÐtransfected fibro-
blasts. Gelatinase A/MMP-2 did not seem to play a role in
this particular process since mock-transfected fibroblasts
were found to express active gelatinase A/MMP-2 but did
not inactivate the inhibitory CNS substrate. Whether
MT1-MMP directly modifies the inhibitory CNS proteins
or whether it acts as an activator in a more complex,
plasma membrane-localized protease cascade remains to
be elucidated (proteases sensitive to low concentrations of
BB94 and TIMP1 are excluded, however). Gelatinase A/
MMP-2 is known to be upregulated in glioblastoma multi-
forme, especially in endothelial cells of blood vessels, sug-
gesting a role for gelatinase A/MMP-2 rather on the level
of angiogenesis (massive neovascularization is a hallmark
of glioblastomas; Sawaya et al., 1996). Itoh et al. (1998) re-
Figure 10. MT1-MMPÐtransfected fibroblasts infiltrated the op-
tic nerves over longer distances than mock-transfected fibro-
blasts. Values are means 6 SEM of 12 nerves infiltrated with
MT1-MMPÐtransfected fibroblasts, 12 nerves with mock-trans-
fected fibroblasts, and eight nerves with C6 cells. Significance
with the two-tailed StudentÕs t test: P , 0.01 (**).
Figure 11. Western blot of bNI-220Ðenriched CNS protein ex-
tract using a polyclonal rabbit antibody against bNI-220 (Huber
et al., 1998). CNS protein extract enriched for bNI-220 was prein-
cubated for 1 h at 378C in the presence of plasma membranes of
C6 cells and transfected fibroblasts. The protein fractions then
were electrophoresed on a 5% SDS polyacrylamide gel, blotted
onto a nitrocellulose membrane, and then probed with purified
antiÐbNI-220 polyclonal rabbit antibody. Bound antibody was vi-
sualized with an peroxidase-conjugated secondary antibody fol-
lowed by chemiluminescent detection. Plasma membranes of C6
glioma cells (PM C6, lane 1) and MT1-MMPÐtransfected fibro-
blasts (PM MT, lane 2) could degrade the bNI-220 completely
(C6 glioma cells) or partially (MT1-MMPÐtransfected fibro-
blasts), whereas mock-transfected fibroblast plasma membranes
could not (PM Mo, lane 3). Digestion of bNI-220 in the presence
of PM MT was blocked by 100 nM TIMP2 (lane 4), but not by
100 nM TIMP1 (lane 5) or 1 mM BB94 (lane 6). Arrow indicates
the bNI-220 level, arrowheads point to a nonspecific band, indi-
cating that in all lanes equal amounts of protein were loaded.Belin et al. Role of MT1-MMP in Diffuse Astrocytomas 383
ported that gelatinase AÐdeficient mice showed reduced
angiogenesis and progression of tumors originating from
implanted melanoma or lung carcinoma cells.
The fact that MT1-MMPÐtransfected fibroblasts were
able to infiltrate adult optic nerve explants to an extent
very similar to C6 glioma cells suggests that MT1-MMP is
crucial for cell migration not only on a two-dimensional
CNS protein substrate, but also within the CNS tissue and,
therefore, probably also in vivo. Stably MT1ÐMMP trans-
fected cell lines may be used to investigate the role of this
protease after implantation into adult rat brains.
The low expression level of MT1-MMP in healthy intact
brain (Yamada et al., 1995) and the high levels of MT1-
MMP found in human gliomas (Okada et al., 1995; Yama-
moto et al., 1996; Uhm et al., 1997), together with the re-
sults of the present study, make MT1-MMP an interesting
potential target for future therapeutic interventions for
diffuse astrocytomas, especially glioblastoma multiforme.
Furthermore, MT1-MMP may serve as a marker and prog-
nostic indicator for the malignancy of astrocytomas.
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